I.e. the non-tradable CVR pays $1.50/ADS* if GC012F receives either FDA accelerated approval for MM within 5 years or FDA full approval for first-line/second-line MM within 6 years.
*Each ADS represents 5 ordinary shares. Hence, the $0.30/sh CVR equates to $1.50/ADS.